Sontina Medical Develop Fast And Low-Cost Breast Biopsy Device

Sontina Medical Develop Fast And Low-Cost Breast Biopsy Device
Breast cancer is the most common cancer in women worldwide, and it is estimated that 1 in 8 women will be diagnosed during their lifetime. Every year, more than 5 million women undergo breast biopsies, the only diagnostic procedure to definitely determine a diagnosis. However, the technology has remained stagnant, and most women are still biopsied using tools that were developed 40 years ago. Improving this technology could help save lives and have tremendous impact on society.

The San Francisco-based startup Sontina Medical is determined to disrupt the breast biopsy industry by introducing a novel biopsy device. Their low-cost, single-use device, called Presto Breast Biopsy Device, allows a physician to fast and easy obtain high-quality samples for breast cancer diagnosis. Instead of taking 5-10 samples with a spring-loaded device, physicians are able to capture 1-3 precision samples using Sontina’s variable length technology. In addition, if multiple samples are needed, it is able to acquire them in a single insertion.

The innovative biopsy device reduce trauma, offering improved patient comfort while maintaining low cost. And the feature giving multiple samples from a single insertion not only makes the biopsy procedure safer and faster, but affordable to the global population. Breast cancer is increasing particularly in developing countries, where the survival rates are the lowest. These low survival rates can be explained mainly by the lack of adequate diagnosis and treatment facilities. Sontina Medical and their device could significantly improve access to a definitive breast cancer diagnosis, potentially improving patient outcomes and survival rates.

The Sontina Medical Presto Breast Biopsy Device is FDA cleared and has been clinically validated. The tissue samples obtained using the device has not only impressed physicians, but made Sontina a semifinalist in the 2016 MedTech Innovator Competition, where they underwent a four month accelerator before attending AdvaMed 2016. Earlier in 2016, the startup also won the Rosenman Innovation Award.